



Republic of the Philippines
Department of Education
REGION VII – CENTRAL VISAYAS
Schools Division Office of Bohol

**Office of the Schools Division
Superintendent**

May 22, 2025

DIVISION MEMORANDUM
No. 320, s. 2025

**DISSEMINATION OF REGIONAL MEMORANDUM NO. 0437, s. 2025
- RE: CANCER WARRIOR CAMPAIGN FOR REGION VII TEACHERS**

To: Schools Division Superintendent
Assistant Schools Division Superintendent
SGOD-Chief
Public School District Supervisors
Public Schools Administrators
School Health Personnel
All other concerned

1. Attached is the **Regional Memorandum No. 0437, s. 2025**, dated May 15, 2025.
2. Kindly refer to the attachments for further details.
3. This Memorandum is for dissemination and compliance is highly desired.


FAY C. LUAREZ EdD, PhD. TM, CESO VI *Hacc.*
OIC - Schools Division Superintendent *po*



Deped Tayo Bohol Division

Address: 0050 Lino Chatto Barangay Cogon,
Tagbilaran City, Bohol
Telephone No.: (038) 411-2544
email Address: deped.bohol@deped.gov.ph
 www.depedbohol.org



Republic of the Philippines
Department of Education
REGION VII - CENTRAL VISAYAS

Office of the Regional Director

REGIONAL MEMORANDUM

No. **0437** s. 2025

15 MAY 2025

CANCER WARRIOR CAMPAIGN FOR REGION VII TEACHERS

To: Schools Division/City Superintendents
Officers-in-Charge of Regular/Interim Divisions
All Others Concerned

1. Attached is a communication from GeneLab PH, expressing their interest to implement the Cancer Warrior Campaign for DepEd Region VII Teachers. This initiative is designed to bring comprehensive cancer education and access to multi-cancer early screening helping safeguard health through timely awareness and intervention.
2. Interested participant to this activity is subject to the discretion and approval of the Schools Division Superintendents or private schools Directors, and to the provisions of DECS Order No. 28, s. 2001 entitled "Prohibiting the Commercialization of DECS organization through Endorsements and Accreditation of Goods and Services", and DepEd Order No. 9, s. 2005 entitled "Instituting Measures to Increase Engaged Time-On Task" and all other existing DepEd policies, regulations and ensuring compliance therewith.
3. The communication is attached for further reference.
4. For the information of all interested and concerned parties.

SALUSTIANO T. JIMENEZ JD, EdD, CESO III
Director IV
Regional Director

STJ/FYA/ESSD/TTP/nam



Doña M. Gaisano St., Sudlon, Lahug, Cebu City
Telephone Number: 639457623193 local 700



DepEd Tayo Region VII



region7.deped.gov.ph



May 5, 2025

SALUSTIANO SALUSTIANO T. JIMENEZ, JD, EdD, CESO III
Director IV
Department of Education, Region VII
Cebu City



Cancer Warrior PH

Through: Mr. Tomas T. Pastor - ESSD

Subject: **CANCER WARRIOR CAMPAIGN FOR REGION 7 TEACHERS**

Dear Director Sal;

On behalf of GeneLab PH, I would like to extend our heartfelt thanks for the opportunity to present the *Cancer Warrior Campaign* during the Department of Education's Regional Management Committee (MANCOM) meeting last April 28. We are honored to have had the platform to share our advocacy, and we deeply appreciate the warm reception and thoughtful engagement from your leadership team.

We firmly believe that the Department of Education plays a critical role in shaping not only the minds but also the long-term health outcomes of our communities. The Cancer Warrior Campaign, designed to promote early detection and education about cancer prevention, is aligned with the DepEd's commitment to the holistic well-being of students, teachers, and staff.

Following our presentation, we would like to formally express our interest in collaborating with your office to implement the Cancer Warrior Campaign within Region 7. This initiative is designed to bring comprehensive cancer education and access to multi-cancer early screening directly to DepEd Region 7 team, helping safeguard their health through timely awareness and intervention.

We are excited about the potential to work in partnership with the Department of Education to create a healthier, more informed school community. Should the region be open to pilot testing or rolling out the initiative, we are ready to provide full support, including training, resources, and coordination with local health providers.


Proposed Areas of Collaboration:

1. Cancer Education

- GeneLab will conduct a series of targeted cancer awareness and education sessions in school divisions. These sessions will highlight the cause, effect, prevention, and importance of early detection and healthy lifestyle choices in cancer prevention and management.

2. Multi-Cancer Early Detection Screening

- In partnership with your office, GeneLab proposes to implement the Multi-Cancer Early Detection Screening among your highly selected qualified employees. Our thoughtfully designed end-to-end patient journey includes the following process;



- Screening Modality: During the performance of the Multi-Cancer Early Detection, we shall utilize the LIQUID BIOPSY FOR MULTI-CANCER EARLY DETECTION FOR ASYMPTOMATIC INDIVIDUALS

SPOT-MAS 10
MULTI-CANCER EARLY DETECTION

- Recommended MCED enables AFFORDABLE CARE & OPPORTUNITY TO BEAT CANCER.
- a cutting-edge technology that can detect multiple cancers at once through a simple blood test.
- Detects a wide range of cancers in their early stages, when they are most treatable.

A breakthrough in Multi-Cancer Early Detection

Spot-Mas 10 is a simple blood test that can detect multiple cancers at once through a simple blood test. It is a cutting-edge technology that can detect multiple cancers at once through a simple blood test. It is a cutting-edge technology that can detect multiple cancers at once through a simple blood test.

- Funding: While GeneLab will manage the education, logistics, diagnostic subsidy up to P22,000.00 per patient, and referral processes, we respectfully request the support of DepEd Region 7 to provide for the Multi-Cancer Early Screening Test Kits through the following;
 - Out-of-pocket direct payments from employees
 - Optional salary deduction schemes
 - Gender and Development (GAD) fund allocations
 - Other appropriate institutional or public funding mechanisms

We wish to highlight that the Cancer Warrior Campaign has already been implemented in collaboration with LGU's and government hospitals. The results have been promising, not only in terms of early cancer detection but also in boosting overall employee morale and promoting a stronger culture of preventive healthcare in the workplace.

We have attached the proposal with detailed costing and specifications of SPOTMAS for your review. And to further discuss the mechanics of the proposed program, and explore the most suitable implementation model for your office. MS. MINERVA JADULCO - Area Manager for Visayas will visit you to help schedule a coordination meeting at your convenience.

Thank you once again for your time, openness, and commitment to supporting initiatives that put people's health first. We look forward to the opportunity of working with your team, together.

Warm regards,



Sarah C. Coe - President, GeneLab Ph
Cancer Warrior

Attachment;

1. Proposal with costing and specifications



Cancer Warrior PH

PROJECT :CANCER WARRIOR PH CAMPAIGN IN DEPED REGION 7

TIMING : Q2 2025

VENUE : TO BE CONFIRMED

BENEFICIARIES : DEPED 7 QUALIFIED PERSONNEL

Activity and Mechanics

Phase 1: Qualification & Selection of Beneficiaries:

1.1 GeneLab in collaboration with the DepEd Region 7 appointed Technical Working Committee shall select high-risk individuals as beneficiaries of the campaign.

1.2 Selection criteria shall be a scoring system based on age, family history, medical history, occupational risk, and lifestyle risk. Please refer to Patient Selection Form.

Phase 2: Cancer Warrior Day

2.2 Pre Test Counseling: Prior to blood extraction, selected high-risk individuals will go through a pre-test counseling for a thorough explanation of the test process and procedure.

2.3 Blood Extraction: *GeneLab's Registered Medical Technologist (RMT) will perform the blood extraction to qualified individuals. 10ml of blood will be collected using the SPOTMAS Test Kits.*

2.4 Send Out: Blood specimens will be shipped-out to GeneLab's laboratory in Singapore and or Vietnam for processing

2.5 Results Distribution: GeneLab will send copy of all test results to attending physician of the individuals or within 15-21 days (upon blood extraction).

Phase 3: Referral:

3.1 Patients with positive findings will be referred to the nearest diagnostic clinic. Genelab Ph do partial reimbursement of the diagnostic tests (as recommended by the test result) up to P22,000.00 (one-time grant) to be paid directly to the diagnostic clinic.

3.1.1 Patients with confirmed positive findings will be referred to the nearest DOH Cancer Hospital for treatment and management.

3.2 Patients with intermediary results will be undergo a repeat SPOTMAS test at no additional cost to the client.

COOPERATION ARRANGEMENT (GENELAB PH - DEPED REGION 7)

I. GENELAB PH

1. Conduct of Continuing Medical Education (CME) & training for relevant health care providers;

1.1 GeneLab shall provide for the CME Speakers, and its transportation to the local venue

2. Implementation of Cancer Warrior Day (in-Hospital) within 7-10 working days upon receipt of P.O. or notice to proceed. The Cancer Warrior Day will include;

2.1. Patient pre-test counseling to be conducted by GeneLab provided facilitator;

2.2. GeneLab will provide the patient selection criteria as basis for the selection and identification of this targeted individuals;

2.3 Provision for blood extraction consumables/supplies (including cotton, alcohol, syringe, etc, disposal) will be provided by GeneLab Ph

3. Provide for logistics at no additional cost to Client, including;

- 1-time delivery of kits to the appointed delivery site on or before the Cancer Warrior Day
- BOQ Clearance and send-out of specimens to GeneLab affiliated laboratory in Singapore or Vietnam within 7 working days upon specimen collection

4. Turn-over of test results to patient-appointed health care provider within 15-21 working days upon specimen collection.

5. Provision of Patient Support to Confirmed Cancer Patient under this project;

Patient Support Programs



1

For patients with a **Positive test result**, up to **USD400** for follow-up diagnostic tests will be provided.



2

Free SPOT-MAS re-test after 6 months with **Positive** result but:

- No lesion detected in imaging tests
OR
- Lesion detected in imaging tests with benign pathology

3

Free SPOT-MAS re-test within 6 months with **Intermediate result**



II. DEPED REGION 7

1. Create a Technical Working Committee (TWC) and designate the focal person, TWC shall include;
 - a. Health Promotion Committee
 - b. Patient Selection Committee
 - c. Pre and Post Test Counseling Committee
2. Provide for venue to accommodate the campaign related activities, including but not limited to;
 - a. Continuing Medical Education for relevant Health Care Providers
 - b. Lay-Fora for the Community
 - c. Cancer Warrior Day (Group Blood Extraction)
3. Coordinate with GeneLab to determine or identify the participants and beneficiaries of the programs, projects and activities to be implemented under the project.
4. Provision of SPOTMAS CtDNA Test Kit through approved funding mechanism.

A. SPOTMAS 5

Covering Specific Organs: Lung, Liver, Colon, Stomach, Breast & others

QTY	UNIT COST	TOTAL
100	P31,000.00	P3,100,000.00
300	P31,000.00	P9,300,000.00
500	P30,700.00	P15,350,000.00
1,000	P29,450.00	P29,450,000.00

B. SPOTMAS 10:

Covering Specific Organs: lung, liver, colon, stomach, breast, pancreas, endometrium, esophagus, head & neck area, ovary & others

QTY	UNIT COST	TOTAL
300	P35,000.00	P10,500,000.00
500	P33,950.00	P16,975,000.00
1,000	P33,250.00	P33,250,000.00

*COST INCLUDES: Training, Supplies, Shipping Cost including BOQ Clearances.
 Excluding VAT.*

Prepared & Submitted by; `



Sarah C. Coe
 President, GeneLab Ph

Specimen: 10 mL blood
 Streck tube
 (in collection kit)

Turn-around time: 30 working days

ctDNA Z-SCORE

Scenario 1: No detected signal. ctDNA Z-score is below the threshold. Result: No cancer detected.

Scenario 2: Detected signal. ctDNA Z-score is above the threshold. Result: Cancer detected.

Scenario 3: Detected signal with tumor origin prediction. ctDNA Z-score is above the threshold. Result: Cancer detected. The tumor origin prediction predicts a 90.0% chance of being lung, 85.0% chance of being breast.

This test was developed by Gene Solutions and is performed at its licensed clinical laboratory in Singapore. Results will be delivered to the ordering physician.

This material is intended for healthcare professionals only.

GENE[®]LAB PH

2204 North Tower, Lee Gardens
 Lee Corner Shaw Blvd., Mandaluyong City
 Mobile: 09278269284

Cancer Warrior PH
 Early Detection Saves Life

GENE SOLUTIONS **GENE[®]LAB PH**

A breakthrough in Multi-Cancer Early Detection

Spot early signals of common and aggressive cancers using next-generation of ctDNA technology

Breast*
 Colorectum*
 Lung*
 Stomach*
 Liver*

Ovary*
 Pancreas*
 Esophagus*
 Uterus*
 Biliary tract*


(*) Standard-of-care screening programs are not available for these 7 cancers (ASCO and American Cancer Society)

SPOT-MAS
 Multi-Cancer Early Detection

What is SPOT-MAS™ test

SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects tumor DNA (ctDNA) circulating in the blood. This test incorporates next-generation sequencing (NGS) and AI technologies to analyze the methylation profile and multiple features of ctDNA, enabling early detection for the most common and aggressive cancers from a single tube of blood.


To know if cancer signs occurred for 16.7% of cancer types and 33.3% of cancer types (ASCO and American Cancer Society, 2022)



Advantages of ctDNA in MCED


- Convenience:** one single blood draw during a healthcare visit.
- Early Detection:** the potential to identify cancer signals at an early stage, before clear symptoms have manifested.
- High accuracy:** high specificity limits false positive and unnecessary work-up.
- Assurance:** capability to test for cancers that do not have recommended screenings to improve early detection opportunities.

SPOT-MAS Performance^{3,4}



100% AI in AI Machine Learning model for Tissue Of Origin Prediction Accuracy. AI Machine Learning model for Tissue Of Origin Prediction Accuracy. AI Machine Learning model for Tissue Of Origin Prediction Accuracy.

Who should consider starting ctDNA screening



Understanding the SPOT-MAS reports

The three possible test results are:

- NEGATIVE**
- A negative result (no ctDNA signal detected yet) does not completely rule out the presence of a tumor because the tumor is out of scope (not 1 of the 10 cancers), is located in a difficult location for ctDNA release¹ or may be asymptomatic metastatic cancer which cannot be detected by this test¹.
 - The negative predictive value of this test is 99.9%^{1,2}, which means that for every 1000 negative cases, about 999 cases actually do not have cancer.
 - This test is recommended for use as a complementary screening test.
 - Patient should continue with existing screening regimens.
- INTERMEDIATE**
- As a ctDNA signal was detected in the subthreshold range, there is insufficient evidence for a definitive conclusion.
 - Advise patient:
 - To repeat this test within 6 months (two or three)
 - To periodically monitor their health and go to a doctor when signs of unwellness or early warning signs of cancer appear.
 - That delaying medical examination when there are suspicious symptoms will lead to the risk of diagnosing cancer at a late stage.
- POSITIVE**
- A ctDNA signal (DNA from tumor) was detected in the blood.
 - This result also provides 1 or 2 predictions about where the cancer signal originates in the body (tissue of origin prediction) with accuracy of 84%.
 - A positive result (ctDNA signal detected) does not completely affirm that a test participant has cancer. The positive predictive value of the test is 58.1%^{1,2}, which means that for every 100 positive cases, about 58 cases will have cancerous or precancerous lesions.
 - Patient should be referred to an oncologist and undergo diagnostic imaging tests. Patient support program for diagnostic imaging is available in Philippines through Gene Solutions.

1. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016). 2. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016). 3. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016). 4. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016). 5. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016). 6. Karpman, et al. "Detection of circulating tumor DNA in early- and late-stage cancer patients." Science Translational Medicine 8(321): 321ra12 (2016).

Adults aged <40 years old with high risks for cancer

- Heavy smoking:** People who have a 20 pack-year history of smoking⁷.
- Heavy drinking:** People who drink 15 cans of beer a week (for men) or 8 cans of beer a week (for women)⁸.
- Hereditary risks:** Those who have had tested positive for inherited cancer genes such as BRCA1/BRCA2, TP53⁹.